Inovio Pharmaceuticals, Inc. (NASDAQ:INO)‘s stock had its “buy” rating reissued by stock analysts at Aegis in a note issued to investors on Tuesday. They presently have a $14.00 price objective on the biopharmaceutical company’s stock. Aegis’ target price suggests a potential upside of 80.18% from the stock’s current price.

A number of other research analysts also recently weighed in on INO. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 3rd. Piper Jaffray Companies raised Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price target on the stock in a research note on Thursday, June 8th. Jefferies Group LLC reaffirmed a “neutral” rating and set a $38.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. BNP Paribas reaffirmed a “neutral” rating and set a $39.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. Inovio Pharmaceuticals has an average rating of “Buy” and a consensus target price of $19.90.

Inovio Pharmaceuticals (NASDAQ INO) traded up 1.03% during mid-day trading on Tuesday, hitting $7.85. The stock had a trading volume of 394,312 shares. The stock has a 50 day moving average of $7.75 and a 200-day moving average of $6.89. The firm’s market cap is $585.82 million. Inovio Pharmaceuticals has a 1-year low of $5.83 and a 1-year high of $11.00.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.31). The firm had revenue of $10.40 million for the quarter, compared to analyst estimates of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the company earned ($0.11) EPS. Analysts predict that Inovio Pharmaceuticals will post ($1.10) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/18/inovio-pharmaceuticals-nasdaqino-buy-rating-reaffirmed-at-aegis.html.

In related news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $8.00, for a total transaction of $64,000.00. Following the completion of the transaction, the director now owns 740,956 shares in the company, valued at $5,927,648. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.60% of the company’s stock.

A number of large investors have recently modified their holdings of the company. Private Capital Advisors Inc. bought a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $274,000. Credit Suisse AG increased its stake in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 69,068 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in shares of Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 4,020 shares during the period. Bank of America Corp DE increased its stake in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 3,605 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Inovio Pharmaceuticals by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 16,845 shares during the period. Hedge funds and other institutional investors own 27.74% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.